Sun Pharma enters into licensing agreement with Ferring to launch CARITEC in India

Sun Pharmaceutical Industries Ltd announced today that one of its wholly-owned subsidiaries has entered into a licence agreement with Ferring Pharmaceuticals Private Limited, a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialise a room temperature stable (RTS) formulation of the obstetric drug, CARITEC (Carbetocin RTS) in India.  

The abovementioned drug is indicated for the prevention of excessive bleeding in women after childbirth. The condition is commonly known as postpartum haemorrhage (PPH). PPH is the leading cause of maternal mortality worldwide, especially in countries like India.  

As per the terms of the agreement, Sun Pharma granted rights for the co-marketing of the drug in India in the private market under the brand name, CARITEC. On the other hand, Ferring has developed the drug and received approval from Drugs Controller General of India (DCGI) for introducing the drug in India.  

On Wednesday, the stock of Sun Pharmaceutical Industries Limited closed at Rs 677.65, up by 0.95 per cent or Rs 6.40 per share. The 52-week high and the 52-week low of the scrip were recorded at Rs 721.90 and Rs 452.60, respectively on BSE.